home / stock / rlftf / rlftf news

RLFTF News and Press, Mondobiotech Holding AG Basel From 07/18/22

Stock Information
Company Name: Mondobiotech Holding AG Basel
Stock Symbol: RLFTF
Market: OTC
Website: relieftherapeutics.com
Menu
RLFTF RLFTF Quote RLFTF Short RLFTF News RLFTF Articles RLFTF Message Board
Get RLFTF Alerts

News, Short Squeeze, Breakout and More Instantly...
RLFTF - Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics ( NASDAQ: ACER ) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sod...
RLFTF - Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)

GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), today announced that its collaboration partner, ACER Therapeutics, Inc. ("Acer"), for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of pati...

RLFTF - Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

Experienced Leader in Commercial and Medical Affairs, With a Focus on Gene Therapy, to Spearhead Relief's New Strategic Foray Into Genetic Medicine GENEVA, SWITZERLAND / ACCESSWIRE / July 18, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a bio...

RLFTF - Relief Therapeutics agrees to acquire a novel dosage form of an already approved prescription drug for the treatment of PKU

Relief Therapeutics Holding ( OTCQB:RLFTF ) said Wednesday that its wholly owned subsidiary, APR Applied Pharma Research SA in pact with Meta Healthcare, has acquired an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exceptio...
RLFTF - Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU

Company acquires an additional therapeutic product for the management of patients with PKU for worldwide markets, with the exception of the United Kingdom, thereby complementing and enhancing its existing PKU GOLIKE ® portfolio of medical products GENEVA, SWITZERLAND / ACCESSWIRE ...

RLFTF - Acer Therapeutics stock rises 10% on Chinese patent for urea cycle disorder therapy

Acer Therapeutics ( NASDAQ: ACER ) is trading 10% higher after it said on Friday that the China National Intellectual Property Administration had issued electronic patent for its drug, ACER-001, to treat patients with urea cycle disorders, rare genetic conditions...

RLFTF - Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form

NEWTON, Mass. and GENEVA, July 08, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced that the China National Intellectual Property Administration (CNIP...
RLFTF - Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 4 to its Registration Statement on Form 20‑F (" Registration Statement ") with the U.S. Securities and Excha...

RLFTF - Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk

GENEVA, SWITZERLAND / ACCESSWIRE / July 4, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Ph...

RLFTF - Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001

Citing the need to inspect a third-party contract packaging manufacturer, the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) The FDA has not raised any approvability concerns related to the efficacy, safety or pharmacokinetics of ACER-001...
Previous 10 Next 10